Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1474168,area,"Although no statistical differences in plasma concentrations and area-under-the-curve at steady state (AUCss) were observed, the oral clearance of pentoxifylline among the smokers (.22 +/- .08 L/minute/kg) was significantly greater (P < .05) than that among the nonsmokers (0.15 +/- 0.06 L/minute/kg) when corrected for body weight.",Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[l] / [kg·min],.22,13761,DB00806,Pentoxifylline
,1474168,oral clearance,"Although no statistical differences in plasma concentrations and area-under-the-curve at steady state (AUCss) were observed, the oral clearance of pentoxifylline among the smokers (.22 +/- .08 L/minute/kg) was significantly greater (P < .05) than that among the nonsmokers (0.15 +/- 0.06 L/minute/kg) when corrected for body weight.",Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[l] / [kg·min],.22,13762,DB00806,Pentoxifylline
,1474168,oral clearance,"Although no statistical differences in plasma concentrations and area-under-the-curve at steady state (AUCss) were observed, the oral clearance of pentoxifylline among the smokers (.22 +/- .08 L/minute/kg) was significantly greater (P < .05) than that among the nonsmokers (0.15 +/- 0.06 L/minute/kg) when corrected for body weight.",Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[l] / [kg·min],0.15,13763,DB00806,Pentoxifylline
,1474168,AUCss,The AUCss of the smokers was 1438 +/- 819 ng.hour/mL and of the nonsmokers was 2864 +/- 1375 ng.hour/mL (P < .02).,Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[h·ng] / [ml],1438,13764,DB00806,Pentoxifylline
,1474168,AUCss,The AUCss of the smokers was 1438 +/- 819 ng.hour/mL and of the nonsmokers was 2864 +/- 1375 ng.hour/mL (P < .02).,Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474168/),[h·ng] / [ml],2864,13765,DB00806,Pentoxifylline
,1517286,lowest detectable concentration,The lowest detectable concentration for all analytes was 25 ng/ml; the recovery was 85%.,Determination of pentoxifylline and its metabolites in human plasma by high-performance liquid chromatography with solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517286/),[ng] / [ml],25,26845,DB00806,Pentoxifylline
,1517286,recovery,The lowest detectable concentration for all analytes was 25 ng/ml; the recovery was 85%.,Determination of pentoxifylline and its metabolites in human plasma by high-performance liquid chromatography with solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517286/),%,85,26846,DB00806,Pentoxifylline
,9504437,maximum plasma concentration (Cmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),[ng] / [ml],485,30790,DB00806,Pentoxifylline
,9504437,maximum plasma concentration (Cmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),[ng] / [ml],646,30791,DB00806,Pentoxifylline
,9504437,maximum plasma concentration (Cmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),[ng] / [ml],735,30792,DB00806,Pentoxifylline
,9504437,maximum plasma concentration (Cmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),[ng] / [ml],781,30793,DB00806,Pentoxifylline
,9504437,time to reach the maximum plasma concentration (Tmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.90,30794,DB00806,Pentoxifylline
,9504437,time to reach the maximum plasma concentration (Tmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.66,30795,DB00806,Pentoxifylline
,9504437,time to reach the maximum plasma concentration (Tmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.31,30796,DB00806,Pentoxifylline
,9504437,time to reach the maximum plasma concentration (Tmax),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.32,30797,DB00806,Pentoxifylline
,9504437,mean residence time (MRT),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,3.8,30798,DB00806,Pentoxifylline
,9504437,mean residence time (MRT),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,2.9,30799,DB00806,Pentoxifylline
,9504437,mean residence time (MRT),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,2.9,30800,DB00806,Pentoxifylline
,9504437,mean residence time (MRT),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,2.7,30801,DB00806,Pentoxifylline
,9504437,elimination half-life (t1/2),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.93,30802,DB00806,Pentoxifylline
,9504437,elimination half-life (t1/2),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.23,30803,DB00806,Pentoxifylline
,9504437,elimination half-life (t1/2),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.39,30804,DB00806,Pentoxifylline
,9504437,elimination half-life (t1/2),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),h,1.23,30805,DB00806,Pentoxifylline
,9504437,volume of distribution at steady state (VdSS/f),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),,11991,30806,DB00806,Pentoxifylline
,9504437,volume of distribution at steady state (VdSS/f),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),,8823,30807,DB00806,Pentoxifylline
,9504437,volume of distribution at steady state (VdSS/f),"The mean values of various pharmacokinetic parameters after drug treatment at these times were, respectively: maximum plasma concentration (Cmax) 485+/-174, 646+/-175, 735+/-271 and 781+/-217 ng mL(-1); time to reach the maximum plasma concentration (Tmax) 1.90+/-0.39, 1.66+/-0.4, 1.31+/-0.41 and 1.32+/-0.44 h, mean residence time (MRT) 3.8+/-0.8, 2.9+/-0.5, 2.9+/-0.4 and 2.7+/-0.3 h, elimination half-life (t1/2) 1.93+/-0.86, 1.23+/-0.3, 1.39+/-0.3 and 1.23+/-0.18 h and volume of distribution at steady state (VdSS/f) 11991+/-4862, 8823+/-3484, 8275+/-2357 and 7063+/-1950 mL kg(-1).",Circadian variations in the pharmacokinetics of pentoxifylline in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504437/),,8275,30808,DB00806,Pentoxifylline
,2178853,elimination half-life,"After a 100 mg intravenous infusion, pentoxifylline elimination half-life was prolonged in cirrhotic patients (2.12 +/- 1.22 hours versus 0.83 +/- 0.29 hours, p less than 0.05) because of a decrease in its plasma clearance (1.44 +/- 0.46 L.hr-1.kg-1 in patients with cirrhosis versus 3.62 +/- 0.75 L.hr-1.kg-1 in volunteers, p less than 0.001).",Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178853/),h,2.12,34572,DB00806,Pentoxifylline
,2178853,elimination half-life,"After a 100 mg intravenous infusion, pentoxifylline elimination half-life was prolonged in cirrhotic patients (2.12 +/- 1.22 hours versus 0.83 +/- 0.29 hours, p less than 0.05) because of a decrease in its plasma clearance (1.44 +/- 0.46 L.hr-1.kg-1 in patients with cirrhosis versus 3.62 +/- 0.75 L.hr-1.kg-1 in volunteers, p less than 0.001).",Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178853/),h,0.83,34573,DB00806,Pentoxifylline
,2178853,plasma clearance,"After a 100 mg intravenous infusion, pentoxifylline elimination half-life was prolonged in cirrhotic patients (2.12 +/- 1.22 hours versus 0.83 +/- 0.29 hours, p less than 0.05) because of a decrease in its plasma clearance (1.44 +/- 0.46 L.hr-1.kg-1 in patients with cirrhosis versus 3.62 +/- 0.75 L.hr-1.kg-1 in volunteers, p less than 0.001).",Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178853/),[l] / [h·kg],1.44,34574,DB00806,Pentoxifylline
,2178853,plasma clearance,"After a 100 mg intravenous infusion, pentoxifylline elimination half-life was prolonged in cirrhotic patients (2.12 +/- 1.22 hours versus 0.83 +/- 0.29 hours, p less than 0.05) because of a decrease in its plasma clearance (1.44 +/- 0.46 L.hr-1.kg-1 in patients with cirrhosis versus 3.62 +/- 0.75 L.hr-1.kg-1 in volunteers, p less than 0.001).",Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178853/),[l] / [h·kg],3.62,34575,DB00806,Pentoxifylline
,2178853,absolute bioavailability,"After oral administration of a 400 mg sustained-released tablet, absolute bioavailability of pentoxifylline increased in cirrhotic patients (0.71 +/- 0.24 versus 0.33 +/- 0.13, p less than 0.01).",Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178853/),,0.71,34576,DB00806,Pentoxifylline
,2178853,absolute bioavailability,"After oral administration of a 400 mg sustained-released tablet, absolute bioavailability of pentoxifylline increased in cirrhotic patients (0.71 +/- 0.24 versus 0.33 +/- 0.13, p less than 0.01).",Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178853/),,0.33,34577,DB00806,Pentoxifylline
,9816047,area under the plasma concentration versus time curve,The median (range) area under the plasma concentration versus time curve for thioTEPA was 29.4 microM/h (26. 2-40.5) and for TEPA was 16.3 microM/h (9.2-21.7 microM-h).,"Dose escalation of N,N',N""-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816047/),[μM] / [h],29.4,53282,DB00806,Pentoxifylline
,9816047,area under the plasma concentration versus time curve,The median (range) area under the plasma concentration versus time curve for thioTEPA was 29.4 microM/h (26. 2-40.5) and for TEPA was 16.3 microM/h (9.2-21.7 microM-h).,"Dose escalation of N,N',N""-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816047/),[μM] / [h],16.3,53283,DB00806,Pentoxifylline
,9816047,maximal plasma concentration,"The median (range) maximal plasma concentration of pentoxifylline and major metabolites I, IV, and V were 1.2 microgram/ml (0.2-7.8), 4.0 microgram/ml (0.5-16.4), 0.4 (range 0.1-0.8), and 2.9 (1.1-5.5), respectively.","Dose escalation of N,N',N""-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816047/),[μg] / [ml],1.2,53284,DB00806,Pentoxifylline
,9816047,maximal plasma concentration,"The median (range) maximal plasma concentration of pentoxifylline and major metabolites I, IV, and V were 1.2 microgram/ml (0.2-7.8), 4.0 microgram/ml (0.5-16.4), 0.4 (range 0.1-0.8), and 2.9 (1.1-5.5), respectively.","Dose escalation of N,N',N""-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816047/),[μg] / [ml],4.0,53285,DB00806,Pentoxifylline
,9816047,maximal plasma concentration,"The median (range) maximal plasma concentration of pentoxifylline and major metabolites I, IV, and V were 1.2 microgram/ml (0.2-7.8), 4.0 microgram/ml (0.5-16.4), 0.4 (range 0.1-0.8), and 2.9 (1.1-5.5), respectively.","Dose escalation of N,N',N""-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816047/),,0.4,53286,DB00806,Pentoxifylline
,9816047,maximal plasma concentration,"The median (range) maximal plasma concentration of pentoxifylline and major metabolites I, IV, and V were 1.2 microgram/ml (0.2-7.8), 4.0 microgram/ml (0.5-16.4), 0.4 (range 0.1-0.8), and 2.9 (1.1-5.5), respectively.","Dose escalation of N,N',N""-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816047/),,2.9,53287,DB00806,Pentoxifylline
,9430774,peak plasma concentrations,"The peak plasma concentrations of pentoxifylline and metabolite I occurred at 15 min after bolus injection and were 9.2 +/- 1.4 and 7.8 +/- 4.3 micrograms/mL, respectively.",The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430774/),[μg] / [ml],9.2,56959,DB00806,Pentoxifylline
,9430774,peak plasma concentrations,"The peak plasma concentrations of pentoxifylline and metabolite I occurred at 15 min after bolus injection and were 9.2 +/- 1.4 and 7.8 +/- 4.3 micrograms/mL, respectively.",The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430774/),[μg] / [ml],7.8,56960,DB00806,Pentoxifylline
,9430774,half-life of elimination (t1/2 beta),The half-life of elimination (t1/2 beta) of pentoxifylline was 1.44 h and volume of distribution (Vdarea) was 0.94 L/kg.,The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430774/),h,1.44,56961,DB00806,Pentoxifylline
,9430774,volume of distribution (Vdarea),The half-life of elimination (t1/2 beta) of pentoxifylline was 1.44 h and volume of distribution (Vdarea) was 0.94 L/kg.,The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430774/),[l] / [kg],0.94,56962,DB00806,Pentoxifylline
,10478991,bioavailability,The bioavailability of the crushed tablets relative to the intact tablets was 156% for the 400-mg strength and 137% for the 600-mg strength.,Administration of crushed extended-release pentoxifylline tablets: bioavailability and adverse effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10478991/),%,156,71031,DB00806,Pentoxifylline
,10478991,bioavailability,The bioavailability of the crushed tablets relative to the intact tablets was 156% for the 400-mg strength and 137% for the 600-mg strength.,Administration of crushed extended-release pentoxifylline tablets: bioavailability and adverse effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10478991/),%,137,71032,DB00806,Pentoxifylline
,3965236,terminal t1/2,"After intravenous pentoxifylline, plasma levels declined in a biphasic manner, with a terminal t1/2 of 1.63 +/- 0.8 hr.",Kinetics of intravenous and oral pentoxifylline in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965236/),h,1.63,71242,DB00806,Pentoxifylline
,3965236,Plasma clearance,Plasma clearance was 1333 +/- 481 ml/min and the volume of distribution was 168 +/- 82.3 l.,Kinetics of intravenous and oral pentoxifylline in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965236/),[ml] / [min],1333,71243,DB00806,Pentoxifylline
,3965236,volume of distribution,Plasma clearance was 1333 +/- 481 ml/min and the volume of distribution was 168 +/- 82.3 l.,Kinetics of intravenous and oral pentoxifylline in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965236/),l,168,71244,DB00806,Pentoxifylline
,3965236,bioavailability,"Urinary excretion of two acid metabolites after oral and intravenous dosing indicated almost complete absorption of drug-related substances from both of the oral formulations, although bioavailability averaged 20% to 30%.",Kinetics of intravenous and oral pentoxifylline in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965236/),%,20,71245,DB00806,Pentoxifylline
,3965236,bioavailability,"Urinary excretion of two acid metabolites after oral and intravenous dosing indicated almost complete absorption of drug-related substances from both of the oral formulations, although bioavailability averaged 20% to 30%.",Kinetics of intravenous and oral pentoxifylline in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965236/),%,30,71246,DB00806,Pentoxifylline
,16721727,tissue-to-serum AUC ratios,"After administration of pentoxifylline, tissue-to-serum AUC ratios ranged from 0.1 for liver and lungs to 0.32 for brain tissue.",Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721727/),,0.1,79648,DB00806,Pentoxifylline
,16721727,tissue-to-serum AUC ratios,"After administration of pentoxifylline, tissue-to-serum AUC ratios ranged from 0.1 for liver and lungs to 0.32 for brain tissue.",Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721727/),,0.32,79649,DB00806,Pentoxifylline
,16721727,AUC ratio,The highest value of metabolite-to-parent AUC ratio (4.98) was observed in lungs.,Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721727/),,4.98,79650,DB00806,Pentoxifylline
,16721727,tissue-to-serum AUC ratios,"When (-)-(R)-M1 was given as a parent drug, tissue-to-serum AUC ratios in liver, kidney, and lungs were very close and ranged from 0.64 to 0.72.",Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721727/),,0.64 to 0.72,79651,DB00806,Pentoxifylline
not exceed,16721727,AUC ratios,"In consequence, metabolite-to-parent AUC ratios did not exceed the value of 0.27.",Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721727/),,0.27,79652,DB00806,Pentoxifylline
,3403100,maximal plasma concentration (Cmax),"After a single oral dose of 400 mg Oxopurin, a mean maximal plasma concentration (Cmax) of 164 +/- 62 micrograms/l was obtained after 2.2 h (tmax).",Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403100/),[μg] / [l],164,86546,DB00806,Pentoxifylline
,3403100,tmax,"After a single oral dose of 400 mg Oxopurin, a mean maximal plasma concentration (Cmax) of 164 +/- 62 micrograms/l was obtained after 2.2 h (tmax).",Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403100/),h,2.2,86547,DB00806,Pentoxifylline
,3403100,peak plasma concentration,"After an identical dose of Trental-400, a peak plasma concentration of 123 +/- 33 micrograms/l was obtained after 2.4 h.",Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403100/),[μg] / [l],123,86548,DB00806,Pentoxifylline
,3403100,relative bioavailability,The mean relative bioavailability of pentoxifylline from Oxopurin was 1.30 +/- 0.19 relative to that of Trental-400.,Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403100/),,1.30,86549,DB00806,Pentoxifylline
,10850837,bioavailability,Mean bioavailability after oral administration ranged from 15 to 32% among treatment groups and was not affected by the presence of food.,Pharmacokinetics of pentoxifylline in dogs after oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850837/),%,15 to 32,94636,DB00806,Pentoxifylline
,19610376,limit of detection,The limit of detection was found to be 5 ng/mL.,Validation of an HPLC method for determination of pentoxifylline in human plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19610376/),[ng] / [ml],5,98025,DB00806,Pentoxifylline
>,19610376,absolute recoveries,The absolute recoveries of pentoxifylline and chloramphenicol from human plasma were >97%.,Validation of an HPLC method for determination of pentoxifylline in human plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19610376/),%,97,98026,DB00806,Pentoxifylline
,9435196,plasma clearance t 1/2,"LSF and its two principal metabolites had plasma clearance t 1/2 values of 0.75 hr, 0.78 hr and 1.17 hr, respectively.",Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435196/),h,0.75,99617,DB00806,Pentoxifylline
,9435196,plasma clearance t 1/2,"LSF and its two principal metabolites had plasma clearance t 1/2 values of 0.75 hr, 0.78 hr and 1.17 hr, respectively.",Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435196/),h,0.78,99618,DB00806,Pentoxifylline
,9435196,plasma clearance t 1/2,"LSF and its two principal metabolites had plasma clearance t 1/2 values of 0.75 hr, 0.78 hr and 1.17 hr, respectively.",Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435196/),h,1.17,99619,DB00806,Pentoxifylline
,31246127,area under the concentration-time curve (AUC),"For PTX, the mean area under the concentration-time curve (AUC), elimination half-life, and volume of distribution increased with dose and ranged from 15.67 to 94.66 h·μg/mL, 0.68 to 0.91 hours, and 0.55 to 0.66 L/kg, respectively, whereas clearance decreased with dose and ranged from 0.42 to 0.64 L/h/kg.",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite after intravenous administration of increasing doses to sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246127/),[h·μg] / [ml],15.67 to 94.66,100652,DB00806,Pentoxifylline
,31246127,elimination half-life,"For PTX, the mean area under the concentration-time curve (AUC), elimination half-life, and volume of distribution increased with dose and ranged from 15.67 to 94.66 h·μg/mL, 0.68 to 0.91 hours, and 0.55 to 0.66 L/kg, respectively, whereas clearance decreased with dose and ranged from 0.42 to 0.64 L/h/kg.",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite after intravenous administration of increasing doses to sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246127/),h,0.68 to 0.91,100653,DB00806,Pentoxifylline
,31246127,volume of distribution,"For PTX, the mean area under the concentration-time curve (AUC), elimination half-life, and volume of distribution increased with dose and ranged from 15.67 to 94.66 h·μg/mL, 0.68 to 0.91 hours, and 0.55 to 0.66 L/kg, respectively, whereas clearance decreased with dose and ranged from 0.42 to 0.64 L/h/kg.",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite after intravenous administration of increasing doses to sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246127/),[l] / [kg],0.55 to 0.66,100654,DB00806,Pentoxifylline
,31246127,clearance,"For PTX, the mean area under the concentration-time curve (AUC), elimination half-life, and volume of distribution increased with dose and ranged from 15.67 to 94.66 h·μg/mL, 0.68 to 0.91 hours, and 0.55 to 0.66 L/kg, respectively, whereas clearance decreased with dose and ranged from 0.42 to 0.64 L/h/kg.",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite after intravenous administration of increasing doses to sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246127/),[l] / [h·kg],0.42 to 0.64,100655,DB00806,Pentoxifylline
,2516344,CIN,Mean CIN of rats coadministered CSA and PTX (942 +/- 214 microliters/min/g KW) was similar to control rats 884 +/- 185 microliters/min/g KW); both were significantly greater than CSA alone (537 +/- 211 microliters/min/g KW; p less than .01).,Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516344/),[μl] / [g·min],942,102658,DB00806,Pentoxifylline
,2516344,CIN,Mean CIN of rats coadministered CSA and PTX (942 +/- 214 microliters/min/g KW) was similar to control rats 884 +/- 185 microliters/min/g KW); both were significantly greater than CSA alone (537 +/- 211 microliters/min/g KW; p less than .01).,Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516344/),[μl] / [g·min],884,102659,DB00806,Pentoxifylline
,2516344,CIN,Mean CIN of rats coadministered CSA and PTX (942 +/- 214 microliters/min/g KW) was similar to control rats 884 +/- 185 microliters/min/g KW); both were significantly greater than CSA alone (537 +/- 211 microliters/min/g KW; p less than .01).,Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516344/),[μl] / [g·min],537,102660,DB00806,Pentoxifylline
,28704725,flow rate,"LSF, PTX and 3-isobutyl 1-methyl xanthine (IBMX, internal standard) were separated on Inertsil® ODS (C18) column (250×4.6mm, 5μm) with mobile phase consisting of A-methanol B-water (50:50v/v) run in isocratic mode at flow rate of 1mL/min for 15min and detection at 273nm.",Simultaneous estimation of lisofylline and pentoxifylline in rat plasma by high performance liquid chromatography-photodiode array detector and its application to pharmacokinetics in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28704725/),[ml] / [min],1,118137,DB00806,Pentoxifylline
,28704725,absolute recoveries,The mean absolute recoveries were found to be 80.47±3.44 and 80.89±3.73% for LSF and PTX respectively.,Simultaneous estimation of lisofylline and pentoxifylline in rat plasma by high performance liquid chromatography-photodiode array detector and its application to pharmacokinetics in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28704725/),%,80.47,118138,DB00806,Pentoxifylline
,28704725,absolute recoveries,The mean absolute recoveries were found to be 80.47±3.44 and 80.89±3.73% for LSF and PTX respectively.,Simultaneous estimation of lisofylline and pentoxifylline in rat plasma by high performance liquid chromatography-photodiode array detector and its application to pharmacokinetics in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28704725/),%,80.89,118139,DB00806,Pentoxifylline
,19645320,flow rate,"HPLC separation of all compounds was carried out on a normal-phase ChiralPak AD column (250 mm x 4.6 mm i.d., 5 mm), using, as a mobile phase, a mixture of hexane and 2-propanol (84:16, v/v) containing 0.01% of diethylamine with a flow rate of 1.5 mL x min(-1).",Validation of a high-performance liquid chromatography method for pharmacokinetic evaluation of pentoxifylline and lisofylline in rat serum and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19645320/),[ml] / [min],1.5,118746,DB00806,Pentoxifylline
,3958924,clearance,The addition of cimetidine resulted in a 37% decrease in pentoxifylline clearance (23.8 +/- 7.5 versus 15.0 +/- 3.2 mL/min; p less than 0.03).,Inhibition of pentoxifylline clearance by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958924/),[ml] / [min],23.8,125913,DB00806,Pentoxifylline
,3958924,clearance,The addition of cimetidine resulted in a 37% decrease in pentoxifylline clearance (23.8 +/- 7.5 versus 15.0 +/- 3.2 mL/min; p less than 0.03).,Inhibition of pentoxifylline clearance by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958924/),[ml] / [min],15.0,125914,DB00806,Pentoxifylline
,25663650,intrinsic hepatic clearance,The estimated intrinsic hepatic clearance was 5.427 ml/min and hepatic clearance calculated using the well-stirred model was 1.22 ml/min.,Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663650/),[ml] / [min],5.427,126340,DB00806,Pentoxifylline
,25663650,hepatic clearance,The estimated intrinsic hepatic clearance was 5.427 ml/min and hepatic clearance calculated using the well-stirred model was 1.22 ml/min.,Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663650/),[ml] / [min],1.22,126341,DB00806,Pentoxifylline
,14506595,bioavailable,Pentoxifylline was readily metabolized and bioavailable (50% +/- 26%).,Dosing regimen and hematologic effects of pentoxifylline and its active metabolites in normal dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506595/),%,50,130553,DB00806,Pentoxifylline
,23400743,T(peak),"Compared with patients with moderate CHF, those with severe CHF showed a significant delay in T(peak) of PTX (3.9 vs 1.6 hours) and M5 (5.6 vs 3.6 hours), a 59% significant increase in M5 AUC, and a 56% nonsignificant increase in PTX AUC.",Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400743/),h,3.9,130622,DB00806,Pentoxifylline
,23400743,T(peak),"Compared with patients with moderate CHF, those with severe CHF showed a significant delay in T(peak) of PTX (3.9 vs 1.6 hours) and M5 (5.6 vs 3.6 hours), a 59% significant increase in M5 AUC, and a 56% nonsignificant increase in PTX AUC.",Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400743/),h,1.6,130623,DB00806,Pentoxifylline
,23400743,T(peak),"Compared with patients with moderate CHF, those with severe CHF showed a significant delay in T(peak) of PTX (3.9 vs 1.6 hours) and M5 (5.6 vs 3.6 hours), a 59% significant increase in M5 AUC, and a 56% nonsignificant increase in PTX AUC.",Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400743/),h,5.6,130624,DB00806,Pentoxifylline
,23400743,T(peak),"Compared with patients with moderate CHF, those with severe CHF showed a significant delay in T(peak) of PTX (3.9 vs 1.6 hours) and M5 (5.6 vs 3.6 hours), a 59% significant increase in M5 AUC, and a 56% nonsignificant increase in PTX AUC.",Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400743/),h,3.6,130625,DB00806,Pentoxifylline
,10514902,Cmax,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ng] / [ml],326.38,134648,DB00806,Pentoxifylline
,10514902,Cmax,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ng] / [ml],266.35,134649,DB00806,Pentoxifylline
,10514902,AUC0-t,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ng] / [h·ml],2424,134650,DB00806,Pentoxifylline
,10514902,AUC0-t,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ng] / [h·ml],2141,134651,DB00806,Pentoxifylline
,10514902,Vss/f,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ml] / [kg],16537,134652,DB00806,Pentoxifylline
,10514902,Vss/f,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ml] / [kg],20136,134653,DB00806,Pentoxifylline
,10514902,Vd/f,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ml] / [kg],11807,134654,DB00806,Pentoxifylline
,10514902,Vd/f,"The mean values of Cmax (326.38 +/- 39.77 vs 266.35 +/- 36.0 ng/ml, p < 0.01, n = 8), AUC0-t (2424 +/- 382 vs 2141 +/- 300 ng/ml/h, p < 0.05, n = 8) were significantly higher and Vss/f (16537 +/- 2869 vs 20136 +/- 5006 ml/kg), Vd/f (11807 +/- 2704 vs 15801 +/- 5960 ml/kg) were significantly (p < 0.05, n = 8) lower following morning (10:00 h) administration than in the night (22:00 h).",Pharmacokinetics of pentoxifylline after oral administration of a sustained release tablet at two different times of the day. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514902/),[ml] / [kg],15801,134655,DB00806,Pentoxifylline
,31175387,Effective concentration (EC50),"Effective concentration (EC50) of PTX in RCO was 8.2 nM and plasma PTX level was 7 nM/mL after single oral dosing of 25 mg/kg, which was 1/6th the clinically used dose.",Reversal of Osteopenia in Ovariectomized Rats by Pentoxifylline: Evidence of Osteogenic and Osteo-Angiogenic Roles of the Drug. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31175387/),nM,8.2,134987,DB00806,Pentoxifylline
,26925505,drug,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),%,74.9,139891,DB00806,Pentoxifylline
,26925505,entrapment efficiency,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),%,74.9,139892,DB00806,Pentoxifylline
,26925505,elasticity,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),1/[mgs],145,139893,DB00806,Pentoxifylline
,26925505,zeta potential,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),mv,-,139894,DB00806,Pentoxifylline
,26925505,zeta potential,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),mv,34.9,139895,DB00806,Pentoxifylline
,26925505,vesi,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),μm,0.69,139896,DB00806,Pentoxifylline
,26925505,PDI,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),,0.11,139897,DB00806,Pentoxifylline
,26925505,permeation flux,"The optimal formulation, F4(Gcholate), exhibited drug entrapment efficiency of 74.9±1.6%, vesicles elasticity of 145±0.6 (mgs(-1)cm(-2)), zeta potential of -34.9±2.2mV, average vesicle diameter of 0.69±0.049μm with PDI of 0.11±0.037 and permeation flux of 56.28±0.19μgcm(-2)h(-1).",Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925505/),1/[(μgcm)^2],56.28,139898,DB00806,Pentoxifylline
,22449008,Maximum,"Maximum and minimum serum concentrations of DCA at steady state in treated mares were 2.40±0.40 μg/mL and 1.06±0.29 μg/mL, respectively.","Disposition of desfuroylceftiofur acetamide in serum, placental tissue, fetal fluids, and fetal tissues after administration of ceftiofur crystalline free acid (CCFA) to pony mares with placentitis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22449008/),[μg] / [ml],2.40,161623,DB00806,Pentoxifylline
,22449008,minimum serum concentrations,"Maximum and minimum serum concentrations of DCA at steady state in treated mares were 2.40±0.40 μg/mL and 1.06±0.29 μg/mL, respectively.","Disposition of desfuroylceftiofur acetamide in serum, placental tissue, fetal fluids, and fetal tissues after administration of ceftiofur crystalline free acid (CCFA) to pony mares with placentitis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22449008/),[μg] / [ml],1.06,161624,DB00806,Pentoxifylline
,22449008,Concentration,Concentration of DCA in colostrum was 1.51±0.60 μg/mL.,"Disposition of desfuroylceftiofur acetamide in serum, placental tissue, fetal fluids, and fetal tissues after administration of ceftiofur crystalline free acid (CCFA) to pony mares with placentitis. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22449008/),[μg] / [ml],1.51,161625,DB00806,Pentoxifylline
,30526026,flow rate,"The analyte and the internal standard were separated from endogenous components on Ace phenyl column using a mixture of 5 mM ammonium acetate buffer and high performance liquid chromatography grade acetonitrile (60:40, v/v) as mobile phase at a flow rate of 1 ml/min.",Development and validation of bioanalytical liquid chromatography-tandem mass spectrometry method for the estimation of pentoxifylline in human plasma: Application for a comparative pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30526026/),[ml] / [min],1,162389,DB00806,Pentoxifylline
,7160423,constant rate,"Subjects were each given either a 25, 50 or 100 mg intravenous loading dose of oxpentifylline followed by an intravenous infusion at a constant rate of 1.5 mg/min for 3 h.",The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160423/),,1,167730,DB00806,Pentoxifylline
,7160423,terminal half-life,"The terminal half-life of oxpentifylline was 1.02 +/- 0.86 h, reflecting a very high clearance of the drug (approx. 3 000 to 6 000 ml/min).",The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160423/),h,1.02,167731,DB00806,Pentoxifylline
,7160423,clearance,"The terminal half-life of oxpentifylline was 1.02 +/- 0.86 h, reflecting a very high clearance of the drug (approx. 3 000 to 6 000 ml/min).",The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160423/),[ml] / [min],3 000 to 6 000,167732,DB00806,Pentoxifylline
,7160423,half-life,"The clearance of a reduced metabolite of oxpentifylline was less than that of the intact drug, although the half-life was similar (0.83 +/- 0.18 h).",The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7160423/),h,0.83,167733,DB00806,Pentoxifylline
,8478997,mean residence time,"After intravenous administration, pentoxifylline was rapidly eliminated (mean residence time 1.09 +/- 0.67 h), had a large steady-state volume of distribution (2.81 +/- 1.16 l/kg), and high clearance (3.06 +/- 1.05 l/kg/h).",Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478997/),h,1.09,168669,DB00806,Pentoxifylline
,8478997,steady-state volume of distribution,"After intravenous administration, pentoxifylline was rapidly eliminated (mean residence time 1.09 +/- 0.67 h), had a large steady-state volume of distribution (2.81 +/- 1.16 l/kg), and high clearance (3.06 +/- 1.05 l/kg/h).",Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478997/),[l] / [kg],2.81,168670,DB00806,Pentoxifylline
,8478997,clearance,"After intravenous administration, pentoxifylline was rapidly eliminated (mean residence time 1.09 +/- 0.67 h), had a large steady-state volume of distribution (2.81 +/- 1.16 l/kg), and high clearance (3.06 +/- 1.05 l/kg/h).",Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478997/),[l] / [h·kg],3.06,168671,DB00806,Pentoxifylline
,8478997,Times to peak concentration,Times to peak concentration ranged from 1-10 h for either dose form.,Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478997/),h,1-10,168672,DB00806,Pentoxifylline
,8478997,relative bioavailability (F'),There was no difference in relative bioavailability (F') between whole (0.98 +/- 0.30) and crushed Trental tablets.,Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478997/),,0.98,168673,DB00806,Pentoxifylline
,15171921,recovery,Mean recovery was determined to be 89.75% for albiflorin and 85.82% for paeoniflorin.,Solid-phase extraction-liquid chromatographic method for the determination and pharmacokinetic studies of albiflorin and paeoniflorin in rat serum after oral administration of Si-Wu decoction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171921/),%,89.75,168841,DB00806,Pentoxifylline
,15171921,recovery,Mean recovery was determined to be 89.75% for albiflorin and 85.82% for paeoniflorin.,Solid-phase extraction-liquid chromatographic method for the determination and pharmacokinetic studies of albiflorin and paeoniflorin in rat serum after oral administration of Si-Wu decoction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171921/),%,85.82,168842,DB00806,Pentoxifylline
,15171921,limit of quantification,"The limit of quantification was 29 ng/ml for albiflorin and 10 ng/ml for paeoniflorin, respectively.",Solid-phase extraction-liquid chromatographic method for the determination and pharmacokinetic studies of albiflorin and paeoniflorin in rat serum after oral administration of Si-Wu decoction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171921/),[ng] / [ml],29,168843,DB00806,Pentoxifylline
,15171921,limit of quantification,"The limit of quantification was 29 ng/ml for albiflorin and 10 ng/ml for paeoniflorin, respectively.",Solid-phase extraction-liquid chromatographic method for the determination and pharmacokinetic studies of albiflorin and paeoniflorin in rat serum after oral administration of Si-Wu decoction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171921/),[ng] / [ml],10,168844,DB00806,Pentoxifylline
,32318890,globule size,The optimized SNEDDS had a mean globule size of 165 nm with minimal turbidity in an aqueous medium.,Improved Oral Pharmacokinetics of Pentoxifylline with Palm Oil and Capmul® MCM Containing Self-Nano-Emulsifying Drug Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32318890/),,165,172348,DB00806,Pentoxifylline
,32318890,AUC,Bioavailability of PTX increased 1.5-folds (AUC = 1013.30 ng h/mL) as SNEDDS than the pure drug with an AUC of 673.10 ng h/mL.,Improved Oral Pharmacokinetics of Pentoxifylline with Palm Oil and Capmul® MCM Containing Self-Nano-Emulsifying Drug Delivery System. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32318890/),[h·ng] / [ml],1013.30,172349,DB00806,Pentoxifylline
,32318890,AUC,Bioavailability of PTX increased 1.5-folds (AUC = 1013.30 ng h/mL) as SNEDDS than the pure drug with an AUC of 673.10 ng h/mL.,Improved Oral Pharmacokinetics of Pentoxifylline with Palm Oil and Capmul® MCM Containing Self-Nano-Emulsifying Drug Delivery System. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32318890/),[h·ng] / [ml],673.10,172350,DB00806,Pentoxifylline
,11401423,rate (Tmax,"PTX reduced the rate (Tmax, 8.58 +/- 2.64 vs 5.66 +/- 1.44 h; K(a); 0.47 +/- 0.14 vs 0.72 +/- 0.19 h(-1)), but not the extent of CBZ absorption at 22:00 h treatment.",Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401423/),h,8.58,174080,DB00806,Pentoxifylline
,11401423,rate (Tmax,"PTX reduced the rate (Tmax, 8.58 +/- 2.64 vs 5.66 +/- 1.44 h; K(a); 0.47 +/- 0.14 vs 0.72 +/- 0.19 h(-1)), but not the extent of CBZ absorption at 22:00 h treatment.",Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401423/),h,5.66,174081,DB00806,Pentoxifylline
,11401423,K(a),"PTX reduced the rate (Tmax, 8.58 +/- 2.64 vs 5.66 +/- 1.44 h; K(a); 0.47 +/- 0.14 vs 0.72 +/- 0.19 h(-1)), but not the extent of CBZ absorption at 22:00 h treatment.",Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401423/),1/[h],0.47,174082,DB00806,Pentoxifylline
,11401423,K(a),"PTX reduced the rate (Tmax, 8.58 +/- 2.64 vs 5.66 +/- 1.44 h; K(a); 0.47 +/- 0.14 vs 0.72 +/- 0.19 h(-1)), but not the extent of CBZ absorption at 22:00 h treatment.",Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401423/),1/[h],0.72,174083,DB00806,Pentoxifylline
,12125034,K(m),"The metabolism of pentoxifylline to (R)-M1 in suspensions of hemolysed erythrocytes followed simple Michaelis-Menten kinetics (K(m) = 11 mM), while that to (S)-M1 was best described by a two-enzyme model (K(m) = 1.1 and 132 mM).",Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125034/),mM,11,178654,DB00806,Pentoxifylline
,12125034,K(m),"The metabolism of pentoxifylline to (R)-M1 in suspensions of hemolysed erythrocytes followed simple Michaelis-Menten kinetics (K(m) = 11 mM), while that to (S)-M1 was best described by a two-enzyme model (K(m) = 1.1 and 132 mM).",Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125034/),mM,1.1,178655,DB00806,Pentoxifylline
,12125034,K(m),"The metabolism of pentoxifylline to (R)-M1 in suspensions of hemolysed erythrocytes followed simple Michaelis-Menten kinetics (K(m) = 11 mM), while that to (S)-M1 was best described by a two-enzyme model (K(m) = 1.1 and 132 mM).",Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125034/),mM,132,178656,DB00806,Pentoxifylline
,12125034,R:S plasma concentration ratio,"In vivo, the R:S plasma concentration ratio of M1 ranged from 0.010-0.025 after intravenous infusion of 300 or 600 mg of pentoxifylline, and from 0.019-0.037 after oral administration of 600 mg.",Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125034/),,0.010-0.025,178657,DB00806,Pentoxifylline
,12125034,R:S plasma concentration ratio,"In vivo, the R:S plasma concentration ratio of M1 ranged from 0.010-0.025 after intravenous infusion of 300 or 600 mg of pentoxifylline, and from 0.019-0.037 after oral administration of 600 mg.",Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125034/),,0.019-0.037,178658,DB00806,Pentoxifylline
,30219998,terminal elimination half-life,"Pharmacokinetic variables of PTX were characterized by a short terminal elimination half-life (1.05 ± 0.19 h), a large volume of distribution (6.30 ± 1.76 L/kg), and high total body clearance (5.31 ± 1.27 L/h/kg).",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite following intravenous administration in cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30219998/),h,1.05,182245,DB00806,Pentoxifylline
,30219998,volume of distribution,"Pharmacokinetic variables of PTX were characterized by a short terminal elimination half-life (1.05 ± 0.19 h), a large volume of distribution (6.30 ± 1.76 L/kg), and high total body clearance (5.31 ± 1.27 L/h/kg).",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite following intravenous administration in cattle. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30219998/),[l] / [kg],6.30,182246,DB00806,Pentoxifylline
,30219998,total body clearance,"Pharmacokinetic variables of PTX were characterized by a short terminal elimination half-life (1.05 ± 0.19 h), a large volume of distribution (6.30 ± 1.76 L/kg), and high total body clearance (5.31 ± 1.27 L/h/kg).",Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite following intravenous administration in cattle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30219998/),[l] / [h·kg],5.31,182247,DB00806,Pentoxifylline
,2751739,Peak plasma levels of radioactivity,Peak plasma levels of radioactivity (4.1-6.2 micrograms eq ml-1) occurred 0.25-0.75 h after administration.,Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751739/),[eq·μg] / [ml],4.1-6.2,183909,DB00806,Pentoxifylline
,2751739,initial half-life,This radioactivity decayed in a biexponential fashion with an initial half-life of 1.01 +/- 0.13 h and a terminal half-life of 36.06 +/- 16.94 h.,Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751739/),h,1.01,183910,DB00806,Pentoxifylline
,2751739,terminal half-life,This radioactivity decayed in a biexponential fashion with an initial half-life of 1.01 +/- 0.13 h and a terminal half-life of 36.06 +/- 16.94 h.,Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751739/),h,36.06,183911,DB00806,Pentoxifylline
,2751739,peak plasma levels,"The peak plasma levels (0.48-2.25 micrograms ml-1) of parent drug, as measured using a specific gas chromatographic assay also occurred at 0.25-0.75 h and subsequently decayed extremely rapidly with an initial half-life of 0.18 +/- 0.15 h and terminal half-life of 0.76 +/- 0.44 h.",Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751739/),[μg] / [ml],0.48-2.25,183912,DB00806,Pentoxifylline
,2751739,initial half-life,"The peak plasma levels (0.48-2.25 micrograms ml-1) of parent drug, as measured using a specific gas chromatographic assay also occurred at 0.25-0.75 h and subsequently decayed extremely rapidly with an initial half-life of 0.18 +/- 0.15 h and terminal half-life of 0.76 +/- 0.44 h.",Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751739/),h,0.18,183913,DB00806,Pentoxifylline
,2751739,terminal half-life,"The peak plasma levels (0.48-2.25 micrograms ml-1) of parent drug, as measured using a specific gas chromatographic assay also occurred at 0.25-0.75 h and subsequently decayed extremely rapidly with an initial half-life of 0.18 +/- 0.15 h and terminal half-life of 0.76 +/- 0.44 h.",Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751739/),h,0.76,183914,DB00806,Pentoxifylline
,19694503,bioavailability,"Pentoxifylline (PTX) is a highly water-soluble, hemorheologic drug that undergoes first-pass effect with 20% bioavailability.",Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694503/),%,20,208279,DB00806,Pentoxifylline
,19694503,zeta potential,"The z-average particle size, zeta potential, and EE% of the SLNs were at least 250 nm, -30.2 mV, and 70%, respectively.",Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694503/),,70,208280,DB00806,Pentoxifylline
,19694503,EE%,"The z-average particle size, zeta potential, and EE% of the SLNs were at least 250 nm, -30.2 mV, and 70%, respectively.",Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694503/),,70,208281,DB00806,Pentoxifylline
,16343291,elimination half-life (t(1/2el)),"The mean elimination half-life (t(1/2el)) of pentoxyfylline was 1.05 h, total body clearance 1.90 L/h x kg, volume of distribution 2.40 L/kg and the mean residence time was 2.73 h, after i.v. administration.",Pharmacokinetics and oral bioavailability of pentoxyfylline in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343291/),h,1.05,210420,DB00806,Pentoxifylline
,16343291,total body clearance,"The mean elimination half-life (t(1/2el)) of pentoxyfylline was 1.05 h, total body clearance 1.90 L/h x kg, volume of distribution 2.40 L/kg and the mean residence time was 2.73 h, after i.v. administration.",Pharmacokinetics and oral bioavailability of pentoxyfylline in broiler chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343291/),[l] / [h·kg],1.90,210421,DB00806,Pentoxifylline
,16343291,volume of distribution,"The mean elimination half-life (t(1/2el)) of pentoxyfylline was 1.05 h, total body clearance 1.90 L/h x kg, volume of distribution 2.40 L/kg and the mean residence time was 2.73 h, after i.v. administration.",Pharmacokinetics and oral bioavailability of pentoxyfylline in broiler chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343291/),[l] / [kg],2.40,210422,DB00806,Pentoxifylline
,16343291,mean residence time,"The mean elimination half-life (t(1/2el)) of pentoxyfylline was 1.05 h, total body clearance 1.90 L/h x kg, volume of distribution 2.40 L/kg and the mean residence time was 2.73 h, after i.v. administration.",Pharmacokinetics and oral bioavailability of pentoxyfylline in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343291/),h,2.73,210423,DB00806,Pentoxifylline
,16343291,maximal plasma concentration,"After oral dosing, mean maximal plasma concentration of pentoxyfylline was 4.01 microg/mL and the interval from p.o. administration until maximum concentration was 1.15 h.",Pharmacokinetics and oral bioavailability of pentoxyfylline in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343291/),[μg] / [ml],4.01,210424,DB00806,Pentoxifylline
,16343291,oral bioavailability,The mean oral bioavailability was found to be 28.2%.,Pharmacokinetics and oral bioavailability of pentoxyfylline in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343291/),%,28.2,210425,DB00806,Pentoxifylline
,30300750,a,We have synthesized Lisofylline-Linoleic acid (LSF-LA) conjugate which self-assembled into micelles (156.9 nm; PDI 0.187; CMC 1 μg/mL; aggregation number 54) without any surfactant and showed enhanced cellular uptake.,Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30300750/),,54,219575,DB00806,Pentoxifylline
,17253910,AUC(0-infinity),"Median pentoxifylline pharmacokinetic parameters after intravenous administration were AUC(0-infinity) 5420 ng x hr/ml, Cmax 16,727 ng/ml, Tmax 5 minutes, k(el) 0.036 minute(-1), and t1/2 19 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),[h·ng] / [ml],5420,234708,DB00806,Pentoxifylline
,17253910,Cmax,"Median pentoxifylline pharmacokinetic parameters after intravenous administration were AUC(0-infinity) 5420 ng x hr/ml, Cmax 16,727 ng/ml, Tmax 5 minutes, k(el) 0.036 minute(-1), and t1/2 19 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),[ng] / [ml],"16,727",234709,DB00806,Pentoxifylline
,17253910,Tmax,"Median pentoxifylline pharmacokinetic parameters after intravenous administration were AUC(0-infinity) 5420 ng x hr/ml, Cmax 16,727 ng/ml, Tmax 5 minutes, k(el) 0.036 minute(-1), and t1/2 19 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),min,5,234710,DB00806,Pentoxifylline
,17253910,k(el),"Median pentoxifylline pharmacokinetic parameters after intravenous administration were AUC(0-infinity) 5420 ng x hr/ml, Cmax 16,727 ng/ml, Tmax 5 minutes, k(el) 0.036 minute(-1), and t1/2 19 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),1/[minute],0.036,234711,DB00806,Pentoxifylline
,17253910,t1/2,"Median pentoxifylline pharmacokinetic parameters after intravenous administration were AUC(0-infinity) 5420 ng x hr/ml, Cmax 16,727 ng/ml, Tmax 5 minutes, k(el) 0.036 minute(-1), and t1/2 19 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),min,19,234712,DB00806,Pentoxifylline
,17253910,AUC(0-infinity),"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),[h·ng] / [ml],4224,234713,DB00806,Pentoxifylline
,17253910,AUC(0-infinity),"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),[h·ng] / [ml],6824,234714,DB00806,Pentoxifylline
,17253910,Cmax,"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),[ng] / [ml],"11,181",234715,DB00806,Pentoxifylline
,17253910,Cmax,"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),[ng] / [ml],"16,758",234716,DB00806,Pentoxifylline
,17253910,Tmax,"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),min,5,234717,DB00806,Pentoxifylline
,17253910,k(el),"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),1/[minute],0.028,234718,DB00806,Pentoxifylline
,17253910,k(el),"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),1/[minute],0.032,234719,DB00806,Pentoxifylline
,17253910,t1/2,"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),min,25,234720,DB00806,Pentoxifylline
,17253910,t1/2,"Median pharmacokinetic parameters after intranasal and intratracheal administration, respectively, were AUC(0-infinity) 4224 and 6824 ng x hr/ml, Cmax 11,181 and 16,758 ng/ml, Tmax 5 and 5 minutes, k(el) 0.028 and 0.032 minute(-1), and t1/2 25 and 22 minutes.",Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253910/),min,22,234721,DB00806,Pentoxifylline
,3216031,area under the curve at steady state,Cimetidine significantly increased (P less than .05) pentoxifylline area under the curve at steady state 26.2% from 675 +/- 97 (mean +/- SEM) to 852 +/- 108 ng.,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),ng,675,235228,DB00806,Pentoxifylline
,3216031,area under the curve at steady state,Cimetidine significantly increased (P less than .05) pentoxifylline area under the curve at steady state 26.2% from 675 +/- 97 (mean +/- SEM) to 852 +/- 108 ng.,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),ng,852,235229,DB00806,Pentoxifylline
,3216031,steady-state plasma concentration,The average steady-state plasma concentration increased 27.4% from 84 +/- 12 to 107 +/- 14 ng/mL (P less than .05).,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),[ng] / [ml],84,235230,DB00806,Pentoxifylline
,3216031,steady-state plasma concentration,The average steady-state plasma concentration increased 27.4% from 84 +/- 12 to 107 +/- 14 ng/mL (P less than .05).,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),[ng] / [ml],107,235231,DB00806,Pentoxifylline
,3216031,Apparent oral clearance,Apparent oral clearance decreased 21.5% from 1309 +/- 304 to 1027 +/- 244 mL/min (P less than .02).,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),[ml] / [min],1309,235232,DB00806,Pentoxifylline
,3216031,Apparent oral clearance,Apparent oral clearance decreased 21.5% from 1309 +/- 304 to 1027 +/- 244 mL/min (P less than .02).,Alteration of pentoxifylline pharmacokinetics by cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216031/),[ml] / [min],1027,235233,DB00806,Pentoxifylline
,24944359,area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞),"Pentoxifylline exhibited nonlinear kinetic characteristics, with median area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞) values of 622, 3428, 8416, and 10,347 ng/mL · h for dose levels 1 to 4, respectively, on study day 1.",Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944359/),[ng] / [h·ml],622,241008,DB00806,Pentoxifylline
,24944359,area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞),"Pentoxifylline exhibited nonlinear kinetic characteristics, with median area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞) values of 622, 3428, 8416, and 10,347 ng/mL · h for dose levels 1 to 4, respectively, on study day 1.",Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944359/),[ng] / [h·ml],3428,241009,DB00806,Pentoxifylline
,24944359,area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞),"Pentoxifylline exhibited nonlinear kinetic characteristics, with median area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞) values of 622, 3428, 8416, and 10,347 ng/mL · h for dose levels 1 to 4, respectively, on study day 1.",Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944359/),[ng] / [h·ml],8416,241010,DB00806,Pentoxifylline
,24944359,area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞),"Pentoxifylline exhibited nonlinear kinetic characteristics, with median area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞) values of 622, 3428, 8416, and 10,347 ng/mL · h for dose levels 1 to 4, respectively, on study day 1.",Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944359/),[ng] / [h·ml],"10,347",241011,DB00806,Pentoxifylline
,31647676,polydispersity index,"In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF-linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF-LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and Nagg: 14.82 at 10 cmc] of methoxypoly(ethylene glycol)-b-poly(carbonate-co-l-lactide) (mPEG-b-P(CB-co-LA)) block copolymer.",Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31647676/),,0.209,261675,DB00806,Pentoxifylline
,31647676,critical micelle concentration (cmc),"In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF-linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF-LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and Nagg: 14.82 at 10 cmc] of methoxypoly(ethylene glycol)-b-poly(carbonate-co-l-lactide) (mPEG-b-P(CB-co-LA)) block copolymer.",Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31647676/),[μg] / [ml],5.95,261676,DB00806,Pentoxifylline
,31647676,Nagg,"In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF-linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF-LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and Nagg: 14.82 at 10 cmc] of methoxypoly(ethylene glycol)-b-poly(carbonate-co-l-lactide) (mPEG-b-P(CB-co-LA)) block copolymer.",Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31647676/),,14.82,261677,DB00806,Pentoxifylline
,31647676,oral bioavailability,PK of LSF-LA PLM (10 mg/kg dose) revealed a significant improvement in oral bioavailability of LSF (74.86%; 3.3-fold increase in comparison to free LSF) and drastic reduction in the drug metabolism.,Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31647676/),%,74.86,261678,DB00806,Pentoxifylline
,3958905,tmax,"Its metabolites, a secondary alcohol and two homologous carboxylic acids showed tmax values from 0.72 to 1.15 hours.",Pharmacokinetics of orally administered pentoxifylline in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958905/),h,0.72 to 1.15,266207,DB00806,Pentoxifylline
,3958905,apparent plasma half-life,The apparent plasma half-life of pentoxifylline varied between 0.39 and 0.84 hours for the various doses while the apparent half-lives of the metabolites were in the range of 0.96 to 1.61 hours.,Pharmacokinetics of orally administered pentoxifylline in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958905/),h,0.39 and 0.84,266208,DB00806,Pentoxifylline
,3958905,apparent half-lives,The apparent plasma half-life of pentoxifylline varied between 0.39 and 0.84 hours for the various doses while the apparent half-lives of the metabolites were in the range of 0.96 to 1.61 hours.,Pharmacokinetics of orally administered pentoxifylline in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958905/),h,0.96 to 1.61,266209,DB00806,Pentoxifylline
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,1.6,267752,DB00806,Pentoxifylline
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,1.7,267753,DB00806,Pentoxifylline
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,1.9,267754,DB00806,Pentoxifylline
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,2.0,267755,DB00806,Pentoxifylline
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,2.1,267756,DB00806,Pentoxifylline
,28903089,run time,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,5,267757,DB00806,Pentoxifylline
,22648913,Cmax,Observed exposure metrics for test and reference products were 140.6±51.5 and 132.6±48.5 ng/ml for Cmax and 986.4±350.7 and 1 035.8±350.3 ng.h/ml for AUC0-24 respectively.,Comparative in vitro dissolution and in vivo bioequivalence of 2 pentoxifylline sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648913/),[ng] / [ml],140.6,272580,DB00806,Pentoxifylline
,22648913,Cmax,Observed exposure metrics for test and reference products were 140.6±51.5 and 132.6±48.5 ng/ml for Cmax and 986.4±350.7 and 1 035.8±350.3 ng.h/ml for AUC0-24 respectively.,Comparative in vitro dissolution and in vivo bioequivalence of 2 pentoxifylline sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648913/),[ng] / [ml],132.6,272581,DB00806,Pentoxifylline
,22648913,AUC0-24,Observed exposure metrics for test and reference products were 140.6±51.5 and 132.6±48.5 ng/ml for Cmax and 986.4±350.7 and 1 035.8±350.3 ng.h/ml for AUC0-24 respectively.,Comparative in vitro dissolution and in vivo bioequivalence of 2 pentoxifylline sustained release formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648913/),[h·ng] / [ml],986.4,272582,DB00806,Pentoxifylline
,22648913,AUC0-24,Observed exposure metrics for test and reference products were 140.6±51.5 and 132.6±48.5 ng/ml for Cmax and 986.4±350.7 and 1 035.8±350.3 ng.h/ml for AUC0-24 respectively.,Comparative in vitro dissolution and in vivo bioequivalence of 2 pentoxifylline sustained release formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648913/),[h·ng] / [ml],1 035.8,272583,DB00806,Pentoxifylline
,8255998,Peak concentrations,"Peak concentrations of pentoxifylline were approximately 10 and 100 micrograms/ml, respectively, with elimination half-lives (+/- 2 SE) of 4.6 (4.2-5.1) and 7.5 (7.2-7.9) min, respectively.",Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8255998/),[μg] / [ml],10,272590,DB00806,Pentoxifylline
,8255998,Peak concentrations,"Peak concentrations of pentoxifylline were approximately 10 and 100 micrograms/ml, respectively, with elimination half-lives (+/- 2 SE) of 4.6 (4.2-5.1) and 7.5 (7.2-7.9) min, respectively.",Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8255998/),[μg] / [ml],100,272591,DB00806,Pentoxifylline
,8255998,elimination half-lives,"Peak concentrations of pentoxifylline were approximately 10 and 100 micrograms/ml, respectively, with elimination half-lives (+/- 2 SE) of 4.6 (4.2-5.1) and 7.5 (7.2-7.9) min, respectively.",Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8255998/),min,4.6,272592,DB00806,Pentoxifylline
,8255998,elimination half-lives,"Peak concentrations of pentoxifylline were approximately 10 and 100 micrograms/ml, respectively, with elimination half-lives (+/- 2 SE) of 4.6 (4.2-5.1) and 7.5 (7.2-7.9) min, respectively.",Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8255998/),min,7.5,272593,DB00806,Pentoxifylline
